Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1 |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, Western blot, other |
| Sample | CRC tissues and cell lines (HCT-116 and HT29), serum |
| Expression Pattern | down-regulated |
| Function Description | Significant decreased levels of MEG3 existed in CRC tissue, cell lines and serum. CRC patients with down-regulated serum MEG3 levels had larger tumor sizes, and advanced clinical stages. The sensitivity and specificity of serum MEG3 levels in CRC detection was 0.667 and 0.875, respectively. Tumor size, T stages, and serum MEG3 levels are indie factors that produce an effect on CRC patients' prognosis. Kaplan-Meier survival curves suggested that CRC patients with high levels of MEG3 had a remarkably better overall survival rate. |
| Pubmed ID | 31413531 |
| Year | 2019 |
| Title | LncRNA MEG3 Acts a Biomarker and Regulates Cell Functions by Targeting ADAR1 in Colorectal Cancer |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |